Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2008

View Archived Issues

Proof-of-concept study supports development of NBI-34041 for anxiety

Postmarketing study finds no increase in nonsuicide death with ziprasidone compared to olanzapine

ASF-1096 investigated in discoid and subacute lupus erythematosus

Aripiprazole data in Asperger's disorder and major depressive disorder reported

Takeda patents use of resatorvid for coronary surgical procedure complications

Pfizer initiates Japanese phase II clinical study of PF-03187207 for glaucoma

NCI files protocol for phase I/II clinical trial of Oncolytics' cancer drug Reolysin

Lundbeck begins phase I clinical studies of Lu-AA-37096 and stops development of Lu-AA-44608

GenVec makes protocol changes to phase II/III PACT trial of TNFerade for pancreatic cancer

ImmunoGen licenses exclusive right to develop IMGN-388 using Centocor antibody

Addex and Merck & Co. to codevelop drug candidate for schizophrenia

FDA approves Shire's new dosages for ADHD treatment Vyvanse

Xanthus' oral fludarabine therapy for CLL receives orphan drug designation

Recent Thallion patent discloses novel antiinfective agents

Recent Bayer patents report novel antithrombotic agents

New phase I/II trial for ispinesib monotherapy in metastatic breast cancer begins

XenoPort begins several clinical trials, gives update on other pipeline products

Amic enters license agreement with Roche Diagnostics for test for cardiac marker NT-proBNP

Takeda submits NDA for alogliptin in the U.S.

Addex announces ADX-10059 phase IIa acute anxiety data

Anti-HIV drug apricitabine enters phase III

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...